Covance Appoints Dr. Raymond Kaiser as Global Science Leader and Vice President for Biotechnology Services
PRINCETON, N.J., October 18, 2011 — Covance Inc. (NYSE: CVD), one of the world’s largest and most comprehensive drug development services companies, today announced that Raymond Kaiser, Ph.D., has joined the company as the new Global Science Leader and Vice President for Biotechnology Services. Kaiser will replace Dr. Carl Martin, who will be retiring from this role, after 35 years with Covance.
Dr. Kaiser comes to Covance from Merck Research Laboratories in West Point, Pa., where he was Executive Director of Bioprocess Research and Development. Dr. Kaiser is a recognized expert in the research, development, quality control and technical support of biologic and vaccine products. Over a 21-year career in the biopharmaceutical industry, he has published more than 50 papers and received patents on various aspects of the development, manufacture and characterization of biologics and vaccines.
During Dr. Kaiser’s tenure with Merck, he had responsibility for the development of novel vaccine and therapeutic protein processes, assays and products. Previously, he was Senior Director of Vaccines Analytical and Formulation Development at Wyeth Vaccines and held a number of scientific leadership positions at Eli Lilly & Company.
Currently, biologics account for approximately 30 percent of all compounds in the pharmaceutical industry’s pipeline. Various industry reports are predicting that by 2015, biologics will account for 50 of the 100 top-selling drugs on the market, making biologic development an important growth focus for the industry.
About Covance Inc.